-
Track & Monitor
Consumer Goods Venture Capital Investments in Q3 2023
GlobalData's Consumer Goods VentureView report provides detailed coverage of the global venture capital investment activity in Consumer Goods industry in Q3 2023, covering key insights and trends.
-
Track & Monitor
Innovation in Ship: Ship loading/unloading cableways
Innovation in the ship industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in ship industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NL-201
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NL-201 Drug Details NL-201 is under development for the treatment of advanced solid tumors, renal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tinostamustine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tinostamustine Drug Details Tinostamustine (NL-101) is under development for the treatment of hematological malignancies...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – mazindol ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry mazindol ER Drug Details Mazindol ER (NSL-0) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NLS-2
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NLS-2 Drug Details Mazindol is under development for the treatment of narcolepsy. The drug candidate...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – mazindol CR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry mazindol CR Drug Details Mazindol is under development for the treatment of attention deficit...